Ergothioneine, Brain Health, and Aging

Some of the most-discussed ergothioneine research concerns the aging brain. Ergothioneine crosses the blood-brain barrier and is detectable in brain tissue, and across several human cohorts, people with lower blood ergothioneine have been more likely to have mild cognitive impairment, dementia, cerebrovascular disease, and physical frailty. Those findings are real and they are consistent — but they are also, so far, associations. This page reports what the studies actually measured, explains the plausible mechanisms, and then draws a firm line: low ergothioneine may be a cause of cognitive decline, or a consequence of it, or simply a marker of the kind of diet and health that protect the brain for other reasons. The first small human trial has only just been run. Read this as a map of an active, promising, early-stage research frontier — not as a recommendation to treat any brain condition with a supplement.

Ergothioneine in the Brain
Low Blood Levels and Cognitive Decline
Mild Cognitive Impairment and Dementia Cohorts
Frailty and Physical Decline in Aging
The Neuroretina and Amyloid
Proposed Neuroprotective Mechanisms
The First Human Trials
What This Does and Does Not Prove
Who Might Be Most at Risk of Low Levels
Practical Guidance
Key Research Papers
Connections
Featured Videos

Ergothioneine in the Brain

For a dietary compound to matter for brain health, it first has to get into the brain — and ergothioneine does. The OCTN1 transporter is expressed at the blood-brain barrier and on neurons, and ergothioneine has been detected in brain tissue and in cerebrospinal fluid. Nakamichi and colleagues, in a 2022 review in Neurochemical Research, summarized the growing evidence that ergothioneine is transported into the central nervous system and may support neuronal health, including a role in neuronal maturation and protection against neurotoxic stress.

This matters because the brain is exquisitely vulnerable to oxidative damage. It burns a fifth of the body's oxygen, is rich in easily oxidized fats, and has neurons that are not readily replaced. An antioxidant that is actively transported into the brain, concentrates where oxidative load is high, and is retained for weeks is, at least in principle, well suited to a protective role there. The question is whether that principle translates into measurable benefit — which is what the human cohort studies set out to test.

Back to Table of Contents

Low Blood Levels and Cognitive Decline

The most direct human evidence comes from a Singapore-based research group who followed community-dwelling older adults and measured their blood ergothioneine. In a 2022 study in Antioxidants, Wu and colleagues reported that older adults with lower plasma ergothioneine at baseline were more likely to show cognitive and functional decline over the following years. Ergothioneine levels also tended to fall with age, meaning the people most exposed to age-related brain risk were often those with the least of this particular antioxidant.

These findings echoed the broader cardiovascular and mortality signal seen in the Swedish Malmö cohort (discussed on the longevity-vitamin page): higher ergothioneine consistently tracks with better outcomes across very different populations and endpoints. Consistency across cohorts strengthens the case that the association is real — though, crucially, it does not by itself establish that ergothioneine is doing the protecting.

Back to Table of Contents

Mild Cognitive Impairment and Dementia Cohorts

The same research line extended into clinical populations. In a 2021 study in Free Radical Biology and Medicine, Wu and colleagues found that among patients being evaluated for cognitive impairment, low plasma ergothioneine was associated not only with dementia but specifically with markers of neurodegeneration and cerebrovascular disease — the small-vessel damage in the brain that contributes heavily to age-related decline. Lower ergothioneine tracked with worse brain imaging findings and worse cognition.

Barry Halliwell, Irwin Cheah, and Richard Tang pulled these threads together in a 2024 review in Free Radical Biology and Medicine provocatively titled "Are age-related neurodegenerative diseases caused by a lack of the diet-derived compound ergothioneine?" The very framing as a question is telling: the field's leading investigators are willing to pose the causal hypothesis out loud, but they pose it as a hypothesis to be tested, not a conclusion already reached. Their answer, in effect, is: it is plausible, the associations are striking, and we now need trials.

Back to Table of Contents

Frailty and Physical Decline in Aging

Cognitive decline rarely travels alone. Frailty — the syndrome of weakness, slowness, exhaustion, and weight loss that makes older adults vulnerable — often accompanies it, and shares oxidative stress and inflammation as underlying drivers. Analyses from the aging cohorts have linked lower ergothioneine to greater frailty and poorer physical function, alongside the cognitive findings.

This fits a coherent picture in which ergothioneine is a marker (and possibly a modifier) of overall biological resilience in aging, rather than something specific to a single organ. A 2025 review by May-Zhang and colleagues in Proceedings of the Nutrition Society surveyed exactly this territory — ergothioneine for cognitive health, longevity, and healthy aging — and reached the now-familiar balanced verdict: consistent and encouraging associations, mechanistic plausibility, and an urgent need for the interventional trials that can settle causation.

Back to Table of Contents

The Neuroretina and Amyloid

The retina is, developmentally, an outgrowth of the brain, and it offers a window onto neurodegeneration. In a 2023 study in Frontiers in Neuroscience, Wijesinghe and colleagues reported that ergothioneine improved the clearance of amyloid-beta — the protein fragment central to Alzheimer's disease — from the neuroretina in an experimental model. Because amyloid accumulation is a hallmark of Alzheimer's disease, any compound that enhances its clearance draws interest.

This is genuinely intriguing mechanistic work, but its status must be stated plainly: it is a preclinical, experimental-model finding about a specific process in retinal tissue. It suggests a mechanism by which ergothioneine could influence neurodegeneration; it does not show that eating more mushrooms clears amyloid from a human brain or prevents dementia. The gap between "improves amyloid clearance in a model system" and "prevents Alzheimer's in people" is enormous, and littered with once-promising compounds that never bridged it.

Back to Table of Contents

Proposed Neuroprotective Mechanisms

If ergothioneine does protect the aging brain, the proposed mechanisms are the same ones detailed on the antioxidant and mitochondria page, applied to neural tissue:

Quenching aggressive oxidants — neutralizing hydroxyl radicals, singlet oxygen, and peroxynitrite that would otherwise damage neuronal lipids, proteins, and DNA.
Protecting mitochondria — neurons are heavily dependent on mitochondrial energy, and mitochondrial failure is central to neurodegeneration.
Restraining neuroinflammation — ergothioneine has anti-inflammatory effects in several models, and chronic low-grade brain inflammation is a driver of decline.
Chelating reactive metals — iron and copper dysregulation contributes to both Alzheimer's and Parkinson's disease, and metal chelation is one of ergothioneine's established chemical actions.
Supporting neuronal maturation — some evidence suggests ergothioneine promotes the growth and maturation of neurons, hinting at a role beyond simple antioxidant defense.

Back to Table of Contents

The First Human Trials

The pivotal step — from association to intervention — is now beginning. In 2024, Yau and colleagues published in the Journal of Alzheimer's Disease an early study investigating whether ergothioneine supplementation could delay cognitive decline in people with mild cognitive impairment. Studies of this kind are exactly what the field has been calling for: they randomize participants to ergothioneine or placebo and measure cognitive outcomes directly, which is the only design that can distinguish cause from correlation.

Such first-in-class trials are typically small and designed mainly to establish safety, feasibility, and preliminary signals rather than to deliver a definitive verdict. They are the opening move, not the final word. Larger, longer trials with hard cognitive endpoints will be needed before anyone can responsibly say that ergothioneine prevents or slows dementia. For now, the honest summary is that the human intervention evidence exists but is in its infancy.

Back to Table of Contents

What This Does and Does Not Prove

What the evidence supports: ergothioneine reaches the brain; lower blood levels are reproducibly associated with cognitive decline, dementia, cerebrovascular disease, and frailty across independent cohorts; and there are coherent, well-characterized mechanisms by which it could be protective.

What the evidence does not establish: that low ergothioneine causes cognitive decline, or that raising it prevents or reverses decline. The alternative explanations remain fully in play — reverse causation (a declining brain and body may lower ergothioneine), and confounding (mushroom-eaters differ from non-mushroom-eaters in dozens of ways). No amount of consistent association can rule these out; only randomized trials can. This is not a pedantic caveat — it is the central, unresolved question of the entire field, and every leading researcher in it says so explicitly.

Back to Table of Contents

Who Might Be Most at Risk of Low Levels

Because ergothioneine comes only from the diet and declines with age, certain groups plausibly run lower:

People who eat few or no mushrooms — the dominant dietary source by a wide margin.
Older adults — blood levels tend to fall with age, for reasons not fully understood.
People with malabsorption or restrictive diets — anything that limits varied whole-food intake can lower it.

None of this rises to the level of a diagnosable "deficiency," because no deficiency disease has been defined. It simply identifies who might most easily raise their intake through diet — which, given that mushrooms are inexpensive, safe, and nutritious in many other ways, is a low-risk thing to do regardless of how the ergothioneine question ultimately resolves.

Back to Table of Contents

Practical Guidance

Eat mushrooms regularly. This is the sensible, evidence-aligned action: it reliably raises ergothioneine and delivers fiber, B vitamins, and other nutrients. The food sources page lists the richest varieties.
Do not substitute a supplement for medical care. If you or a family member has memory concerns, that warrants proper evaluation for the many treatable contributors to cognitive change — not a self-prescribed antioxidant.
Keep expectations calibrated. The current science justifies interest and a mushroom-rich diet, not claims that ergothioneine treats or prevents dementia.
Follow the trials. The next few years of randomized studies will determine whether the strong associations reflect a genuine, actionable benefit.

Back to Table of Contents

Key Research Papers

Wu LY et al. (2022). Low Plasma Ergothioneine Predicts Cognitive and Functional Decline in an Elderly Cohort. Antioxidants (Basel) 11(9):1717. — PubMed 36139790
Wu LY et al. (2021). Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia. Free Radical Biology and Medicine 177:201–211. — PubMed 34673145
Halliwell B, Tang RMY, Cheah IK (2024). Are age-related neurodegenerative diseases caused by a lack of the diet-derived compound ergothioneine? Free Radical Biology and Medicine. — PubMed 38492784
Yau YF et al. (2024). Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects. Journal of Alzheimer's Disease. — PubMed 39544014
Wijesinghe P et al. (2023). Ergothioneine, a dietary antioxidant improves amyloid beta clearance in the neuroretina. Frontiers in Neuroscience. — PubMed 36998724
Nakamichi N et al. (2022). Ergothioneine and central nervous system diseases. Neurochemical Research. — PubMed 35788879
Paul BD (2022). Ergothioneine: A Stress Vitamin with Antiaging, Vascular, and Neuroprotective Roles? Antioxidants & Redox Signaling 36(16–18):1306–1317. — PubMed 34619979
May-Zhang LS et al. (2025). Ergothioneine for cognitive health, longevity and healthy ageing: where are we now? Proceedings of the Nutrition Society. — PubMed 40968729
Cheah IK et al. (2017). Administration of Pure Ergothioneine to Healthy Human Subjects. Antioxidants & Redox Signaling 26(5):193–206. — PubMed 27488221